Industry News (Therapy)

Oligonucleotide-Based Drugs To Treat HBV

Published in Gene Therapy Weekly, January 29th, 1996

Innovir Laboratories, Inc., New York, New York, announced that several of its lead oligonucleotide-based drugs, called External Guide Sequences (EGSs), have shown potent anti-viral activity against hepatitis B virus (HBV) in preclinical research.

Tests conducted by Dr. Brent Korba of Georgetown University, Washington, D.C., under a contract from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH), in an HBV-producing human cell line demonstrated that a number of the company's EGS compounds were comparable or nearly comparable to the anti-HBV activity of the nucleoside analog 3TC.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry